Faron Pharmaceuticals Oy

As of June 30, 2026, Faron Pharmaceuticals Oy carries a market capitalization of 8.32B, placing it among publicly traded companies globally. Its enterprise value stands at 7.11B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Faron Pharmaceuticals Oy's next confirmed earnings release is scheduled for March 19, 2027.

As of June 30, 2026, Faron Pharmaceuticals Oy has 202.88M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Faron Pharmaceuticals Oy maintains a current ratio of 2.40, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Faron Pharmaceuticals Oy's stock has declined approximately 80.05% over the past 52 weeks. The 50-day moving average sits at 36.98, while the 200-day moving average is 55.97.

As of June 30, 2026, Faron Pharmaceuticals Oy holds 2.75B in cash and equivalents against 1.54B in total debt, resulting in a net debt position of -1.22B. Total book value stands at 995.71M, with working capital of 1.69B providing operational flexibility.

Faron Pharmaceuticals Oy's most recent stock split took place on March 11, 2026 with a 71:74 split ratio.